S-thanatin enhances the efficacy of tigecycline in an experimental rat model of polymicrobial peritonitis

Peptides

Volumn 31, Issue 7, 2010, Pages 1231-1236

  Cirioni, Oscar ^a   Wu, Guoqiu ^b   Li, Linxian ^c   Orlando, Fiorenza ^d   Silvestri, Carmela ^a   Ghiselli, Roberto ^a   Shen, Zilong ^c   Scalise, Alessandro ^a   Gabrielli, Eleonora ^a   Scuppa, Daniele ^a   Romiti, Chiara ^a   Provinciali, Mauro ^d   Guerrieri, Mario ^a   Giacometti, Andrea ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b SOUTHEAST UNIVERSITY   (China)

^c CHINA PHARMACEUTICAL UNIVERSITY   (China)

^d INRCA   (Italy)

Author keywords

Antimicrobial peptides; Polymicrobial peritonitis; S thanatin; Tigecycline

Indexed keywords

NITRIC OXIDE; POLYPEPTIDE ANTIBIOTIC AGENT; SODIUM CHLORIDE; THANATIN; TIGECYCLINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL PERITONITIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; LETHALITY; MALE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; RAT; SEPSIS;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; DISEASE MODELS, ANIMAL; MALE; MINOCYCLINE; MODELS, ANIMAL; PERITONITIS; RATS; RATS, WISTAR; TREATMENT OUTCOME;

ANIMALIA; BACTERIA (MICROORGANISMS); RATTUS; RATTUS NORVEGICUS;

EID: 77952549104     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2010.03.034     Document Type: Article

References (39)

1. Benjamin C.F., Silva J.S., Fortes Z.B., Oliveira M.A., Ferreira S.H., and Cunha F.Q. Inhibition of leukocyte rolling by nitric oxide during sepsis leads to reduced migration of active microbicidal neutrophils. Infect Immun 70 (2002) 3602-3610
2. Castillo M., Toledo-Pereyra L.H., Gutierrez R., Prough D., and Shapiro E. Peritonitis after cecal perforation. Am Surg 57 (1991) 313-316
3. Cirioni O., Ghiselli R., Kamysz W., Orlando F., Silvestri C., Mocchegiani F., et al. Tachyplesin III and granulocyte-colony stimulating factor enhance the efficacy of piperacillin/tazobactam in a neutropenic mouse model of polymicrobial peritonitis. Peptides 29 (2008) 31-38
4. Cirioni O., Silvestri C., Ghiselli R., Giacometti A., Orlando F., Mocchegiani F., et al. Experimental study on the efficacy of combination of α-helical antimicrobial peptides and vancomycin against Staphylococcus aureus with intermediate resistance to glycopeptides. Peptides 27 (2006) 2600-2606
5. Clinical Laboratory Standards Institute (CLSI). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard M7-A6 (2003), Clinical and Laboratory Standards Institute (CLSI), Villanova, PA
6. Diekema D.J., BootsMiller B.J., Vaughn T.E., Woolson R.F., Yankey J.W., Ernst E.J., et al. Antimicrobial resistance trends and outbreak frequency in United States hospitals. Clin Infect Dis 38 (2004) 78-85
7. Doyle J., Brinkworth C.S., Wegener K.L., Carver J.A., Llewellin L.E., Olver I.N., et al. nNOS inhibition, antimicrobial and anticancer activity of the amphibian skin peptide, citropin 1.1 and synthetic modifications. The solution structure of a modified citropin 1.1. Eur J Biochem 270 (2003) 1141-1153
8. Eliopoulos G.M., and Moellering Jr. R.C. Antimicrobial combinations. In: Lorian V. (Ed). Antibiotics in laboratory medicine (1996), Williams & Wilkins, Baltimore, MD 330-393
9. Fehlbaum P., Bulet P., Chemysh S., Briand J.P., Roussel J.P., Letellier L., et al. Structure activity analysis of thanatin, a 21-residue inducible insect defense peptide with sequence homology to frog skin antimicrobial peptides. Proc Natl Acad Sci 93 (1996) 1221-1225
10. Ganz T. Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol 3 (2003) 710-720
11. Hancock R.E.W. Cationic peptides: effectors in innate immunity and novel antimicrobials. Lancet Infect Dis 1 (2001) 156-164
12. Hancock R.E.W., and Diamond G. The role of cationic antimicrobial peptides in innate host defences. Trends Microbiol 8 (2000) 402-410
13. Imamura T., Yamamoto N., Tamura A., Murabayashi S., Hashimoto S., Shimada H., et al. NMR based structure-activity relationship analysis of an antimicrobial peptide, thanatin, engineered by site-specific chemical modification: activity improvement and spectrum alteration. Biochem Biophys Res Commun 369 (2008) 609-615
14. Kokryakov V.N., Harwig S.S.L., Panyutich E.A., Shevchenko A.A., Aleshina G.M., Shamova O.V., et al. Protegrins: leukocyte antimicrobial peptides that combine features of corticostatic defensins and tachyplesins. FEBS Lett 2 (1993) 231-236
15. Koksal G.M., Sayilgan C., Aydin S., Oz H., and Uzun H. Correlation of plasma and tissue oxidative stresses in intra-abdominal sepsis. J Surg Res 122 (2004) 180-183
16. Levy R.M., Prince J.M., and Billiar T.R. Nitric oxide: a clinical primer. Crit Care Med 33 (2005) S492-S495
17. Manocha S., Feinstein D., Kumar A., and Kumar A. Novel therapies for sepsis: antiendotoxin therapies. Expert Opin Investig Drugs 11 (2002) 1795-1812
18. McCafferty D.G., Cudic P., Yu M.K., Behenna D.C., and Kruger R. Synergy and duality in peptide antibiotic mechanisms. Curr Opin Chem Biol 3 (1999) 672-680
19. Mullangi P.K., and Pankey G.A. Tigecycline in critical care. Crit Care Clin 24 (2008) 365-375
20. Noskin G.A. Tigecycline: a new glycylcycline for treatment of serious infections. Clin Infect Dis 41 (2005) S303-S314
21. Orlando F., Ghiselli R., Cirioni O., Minardi D., Tomasinsig L., Mocchegiani F., et al. BMAP-28 improves the efficacy of vancomycin in rat models of Gram-positive cocci ureteral stent infection. Peptides 29 (2008) 1118-1123
22. Parker S.J., and Watkins P.E. Experimental models of Gram-negative sepsis. Br J Surg 88 (2000) 22-30
23. Remick D.G., Newcomb D.E., Bolgos G.L., and Call D.R. Comparison of the mortality and inflammatory response of two models of sepsis: lipopolysaccharide vs. cecal ligation and puncture. Shock 13 (2000) 110-116
24. Saklayen M.G. CAPD peritonitis: incidence, pathogens, diagnosis, and management. Med Clin North Am 74 (1990) 997-1010
25. Sharma V.K., and Dellinger R.P. Recent developments in the treatment of sepsis. Expert Opin Investig Drugs 12 (2003) 139-152
26. Simonetti O., Cirioni O., Goteri G., Ghiselli R., Silvestri C., Orlando F., et al. Temporin A is effective in the MRSA infected wounds in mice through bactericidal activity and acceleration of wound repair. Peptides 29 (2008) 520-528
27. Swoboda S., Ober M., Hainer C., Lichtenstern C., Seiler C., Wendt C., et al. Tigecycline for the treatment of patients with severe sepsis or septic shock: a drug use evaluation in a surgical intensive care unit. J Antimicrob Chemother 61 (2008) 729-733
28. Tracey K.J., and Abraham E. From mouse to man: or what have we learned about cytokine-based anti-inflammatory therapies?. Shock 11 (1999) 224-225
29. Ulloa L., Brunner M., Ramos L., and Deitch E.A. Scientific and clinical challenges in sepsis. Curr Pharm Des 15 (2009) 1918-1935
30. Vaara M., and Porro M. Group of peptides that act synergistically with hydrophobic antibiotics against Gram-negative enteric bacteria. Antimicrob Agents Chemother 40 (1996) 1801-1805
31. Vergidis P.I., and Falagas M.E. New antibiotic agents for bloodstream infections. Int J Antimicrob Agents 32 (2008) S60-S65
32. Wang H.D., Lu D.X., and Qi R.B. Therapeutic strategies targeting the LPS signaling and cytokines. Pathophysiology 16 (2009) 291-296
33. Wheeler A.P., and Bernard G.R. Treating patients with severe sepsis. N Engl J Med 304 (1999) 207-214
34. Wong K.F., and Luk J.M. Endotoxin-neutralizing peptides as Gram-negative sepsis therapeutics. Protein Pept Lett 16 (2009) 539-542
35. Wu G.Q., Ding J.X., Li H., Li L., Zhao R., Shen Z., et al. Effects of cations and pH on antimicrobial activity of thanatin and s-thanatin against Escherichia coli ATCC 25922 and B. subtilis ATCC 21332. Curr Microbiol 57 (2008) 552-557
36. Wu G.Q., Li L.X., Ding J.X., Wen L.Z., and Shen Z.L. High level expression and novel purification strategy of recombinant thanatin analog in Escherichia coli. Curr Microbiol 57 (2008) 95-101
37. Yang D., Biragyn A., Kwak L.W., and Oppenheim J.J. Mammalian defensins in immunity: more than just microbicidal. Trends Immunol 23 (2002) 291-296
38. Yeaman M.R., and Yount N.Y. Mechanisms of antimicrobial peptide action and resistance. Pharmacolol Rev 55 (2003) 27-55
39. Zasloff M. Antimicrobial peptides of multicellular organisms. Nature 415 (2002) 389-395